Feb 23 (Reuters) - Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
One division will house its cancer drugs, including Keytruda, while the other will sell its non-cancer products.
Advertisement
Merck did not respond to a Reuters request for comment immediately.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)
